why choose us

First received: September 16, 2022

Clinical Trial: A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Facioscapulohumeral Muscular Dystrophy (FSHD)

Study Type: INTERVENTIONAL


Official Title: A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Pharmacodynamics, Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7204239 in Participants With Fac

Brief Summary: The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and efficacy of RO7204239, a humanized monoclonal antibody that binds to human latent myostatin, in ambulant adult participants with facioscapulohumeral muscular dystrophy (FSHD).

Read more